In pediatrics, HDAC inhibitors are primarily being investigated for their potential use in treating various cancers and genetic disorders. In particular, they have shown promise in the treatment of pediatric cancers such as neuroblastoma, medulloblastoma, and certain types of leukemia. Additionally, research is ongoing to explore their utility in managing neurodevelopmental disorders and inflammatory conditions.
